ISRCTN89337058 https://doi.org/10.1186/ISRCTN89337058

Assessment of the immunogenicity and safety of the Northern Hemisphere 2010/2011-season influenza vaccine in elderly and young subjects according to European Medicines Agency (EMEA) regulations

Submission date	Recruitment status	[_] Prospectively registered
12/05/2010	No longer recruiting	[_] Protocol
Registration date	**Overall study status**	[_] Statistical analysis plan
21/01/2011	Completed	[_] Results
Last Edited	**Condition category**	[_] Individual participant data
08/02/2023	Infections and Infestations	[_] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Michael Seiberling

Contact details
Covance Clinical Research Unit AG
Lettenweg 118
Allschwil
Switzerland
4123

Additional identifiers

Protocol serial number
INF-V-A004

Study information

Scientific Title
Assessment of the immunogenicity and safety of the Northern Hemisphere 2010/2011-season influenza vaccine in elderly and young subjects according to European Medicines Agency (EMEA) regulations: an open label, non-randomised uncontrolled safety and efficacy study

Study objectives
The Northern Hemisphere 2010/2011-season influenza vaccine fulfills the European Medicines Agency (EMEA) requirements for re-registration of influenza vaccines.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Local Medical Ethics Committee (Ethikkommission beider Basel [EKBB]), Switzerland, approved on the 21 April 2010

Primary study design
Interventional

Study design
Open non-randomised uncontrolled safety/efficacy study

Study type(s)
Prevention

Health condition(s) or problem(s) studied
Influenza

Interventions
Biological: single dose of trivalent virosomal adjuvanted influenza vaccine (Inflexal® V). Total duration of follow-up: approximately three weeks.

Intervention Type
Biological/Vaccine

Phase
Not Applicable

Primary outcome(s)
Immunogenicity, assessed by haemagglutination inhibition test; blood to be collected before, one, two and approximately three weeks after vaccination.

Key secondary outcome(s)
Safety, assessed at baseline and at three weeks after vaccination, including a four-day adverse event questionnaire, soliciting a set of local and systemic adverse events (AEs) according to the European Medicines Agency (EMEA) specifications.

Completion date
31/07/2010

Eligibility

Key inclusion criteria
1. Healthy female and male volunteers equal to or older than 18 years of age on the day of enrolment
2. Written informed consent

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Lower age limit
18 Years

Sex
All

Key exclusion criteria
1. Pregnancy and lactation
2. Serious adverse reaction to any influenza vaccine

Date of first enrolment
01/06/2010

Date of final enrolment
31/07/2010

Locations

Countries of recruitment
Switzerland

Study participating centre
Covance Clinical Research Unit AG
Allschwil
Switzerland
4123

Sponsor information

Organisation
Crucell Switzerland AG (Switzerland)

Funder(s)

Funder type
Industry

Funder Name
Crucell Switzerland AG (Switzerland)

Results and Publications

Individual participant data (IPD) sharing plan
Not provided at time of registration

IPD sharing plan summary
Not provided at time of registration